万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
乳腺癌和卵巢癌易感基因RAD51C抗体
- 抗体英文名:
Anti-RAD51C
- 靶点:
详见说明书
- 浓度:
1mg/1ml
- 应用范围:
WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
- 宿主:
详见说明书
- 供应商:
上海一研
- 库存:
29
- 级别:
详见说明书
- 目录编号:
详见说明书
- 抗原来源:
Rabbit
- 保质期:
详见说明书
- 适应物种:
详见说明书
- 标记物:
详见说明书
- 克隆性:
多克隆
- 保存条件:
Store at -20 °C
- 形态:
详见说明书
- 亚型:
IgG
- 免疫原:
KLH conjugated synthetic peptide derived from human RAD51C C-terminus
- 规格:
0.2ml/200μg
英文名称 Anti-RAD51C
中文名称 乳腺癌和卵巢癌易感基因RAD51C抗体图片
别 名 tudor domain containing 1; Tdrd1; MTR-1; FLJ21082; CT41.1; TDRD1_HUMAN.
浓 度 1mg/1ml
规 格 0.2ml/200μg
抗体来源 Rabbit
克隆类型 polyclonal
交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse
产品类型 一抗
研究领域 肿瘤 细胞生物 表观遗传学
蛋白分子量 predicted molecular weight: 132kDa
性 状 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human RAD51C C-terminus
亚 型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
产品应用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
产品介绍 Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. The RAD51B-RAD51C dimer exhibits single-stranded DNA-dependent ATPase activity. The BCDX2 complex binds single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. Participates in branch migration and Holliday junction resolution and thus is important for processing HR intermediates late in the DNA repair process. Also has an early function in DNA repair in facilitating phosphorylation of the checkpoint kinase CHK2 and thereby transduction of the damage signal, leading to cell cycle arrest and HR activation. Protects RAD51 from ubiquitin-mediated degradation that is enhanced following DNA damage. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51 and XRCC3. Contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Involved in maintaining centrosome number in mitosis.
Function : Plays a central role during spermatogenesis by participating in the repression transposable elements and prevent their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for the localization of Piwi proteins to the meiotic nuage. Involved in the piRNA metabolic process by ensuring the entry of correct transcripts into the normal piRNA pool and limiting the entry of cellular transcripts into the piRNA pathway. May act by allowing the recruitment of piRNA biogenesis or loading factors that ensure the correct entry of transcripts and piRNAs into Piwi proteins
Subunit : Found in a mRNP complex, at least composed of TDRD1, TDRD6, TDRD7 and DDX4. Interacts with MAEL. Interacts with PIWIL1, PIWIL2 and PIWIL4 (when methylated on arginine residues)
Subcellular Location : Cytoplasm. Note=Component of the meiotic nuage, also named P granule, a germ-cell-specific organelle required to repress transposon during meiosis. Also present in chromatoid body.
Tissue Specificity : Expressed in a variety of tissues, with highest expression in testis, heart muscle, spleen and prostate.
Similarity : Belongs to the TDRD1 family.
Contains 1 MYND-type zinc finger.
Contains 4 Tudor domains.
乳腺癌和卵巢癌易感基因RAD51C抗体图片储存温度:
存在于血清、组织培养上清液或腹水中的抗体在-20℃下能够长期储存。低温存放不会损伤抗体活性。抗体的工作液通常储存于4℃中。此温度下,抗体的活性能稳定数月至数年亦不损失。抗体溶液不应反复冻融,因为反复冻融将导致部分抗体失活并产生不需要的蛋白—蛋白凝聚物。抗体的凝聚能导致活性丧失。这是由于抗原结合位点的空间构象被破坏,或由于产生的不溶物被离心或过滤而除去。冷凝蛋白类的抗体不能存放于4℃。因为在4℃下此类抗体会发生沉淀。一些鼠源性IgG3亚类的抗体有此特性。如果抗体在4℃下发生沉淀,就应该存放于室温下的叠氮钠溶液中。
乳腺癌和卵巢癌易感基因RAD51C抗体图片的分类:
按作用对象,可将其分为抗毒素、抗菌抗体、抗病毒抗体和亲细胞抗体(能与细胞结合的免疫球蛋白,如1型变态反应中的lgE反应素抗体,能吸附在靶细胞膜上);按理化性质和生物学功能,可将其分为IgM、IgG、IgA、IgE、IgD五类;按抗体的来源,可 将其分为天然抗体和免疫抗体。抗体就是免疫球蛋白,是改变了的球蛋白分子。由特异性抗原刺激产生,抗体的产生是由于抗原侵入人体后引起各种免疫细胞相互作用,使淋巴细胞中的B细胞分化增殖而形成浆细胞,浆细胞可产生分泌抗体。
CD93/C1qrpCD93抗体规格:0.2ml
TSHB小鼠抗促甲状素抗体规格:0.1ml
CHMP1A染色质修饰蛋白1A抗体规格:0.2ml
MouseAnti-rabbitIgG/Cy5.5Cy5.5标记的小鼠抗兔IgG规格:0.1ml
DOK2D酪氨酸激酶衰减蛋白2抗体规格:0.1ml
phospho-KIP(Ser153)磷酸化Raf激酶抑制蛋白抗体规格:0.1ml
PD-1/CD279程序性死亡1抗体规格:0.1ml
CPN2羧肽酶CPN2抗体规格:0.2ml
SUMO1类泛素蛋白抗体规格:0.1ml
CACH3/CaV1.3L型钙通道蛋白a1亚型3抗体规格:0.2ml
Pinin桥粒相关蛋白DRS抗体规格:0.2ml
Ki-67(ProliferationMaKer)Ki67蛋白抗体规格:0.1ml
ACVRL1/ALK1激活素受体样激酶1抗体规格:0.2ml
NSDHL类固醇脱酶样蛋白NSDHL抗体规格:0.2mlAllatostatin VI Tyr-Pro-Gln-Glu-His-Arg-Phe-Ser-Phe-Gly-Leu-NH2
Annexin 1 (ANXA-1; Ac 2-12) Ac-Ala-Met-Val-Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp
bFGF Inhibitory Peptide II Met-Trp-Tyr-Arg-Pro-Asp-Leu-Asp-Glu-Arg-Lys-Gln-Gln-Lys-Arg-Glu
Biotin-Secretin, human Biotin-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2
C. difficile Toxin B (529-536) Ala-Gln-Phe-Glu-Glu-Tyr-Lys-Arg
CEA (605-613) Tyr-Leu-Ser-Gly-Ala-Asn-Leu-Asn-Leu
C-Reactive Protein (CRP) (77-82) Val-Gly-Gly-Ser-Glu-Ile
Dynorphin A (1-11), porcine Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys
Eptifibatide Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH2(Disulfide bridge, Mpa1-Cys6)
Galanin-Lys(Biotin), human Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-乳腺癌和卵巢癌易感基因RAD51C抗体图片 Hydrin 1‘ Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-Gly-Lys (Disulfide bridge: Cys1-Cys6)
Katacalcin Asp-Met-Ser-Ser-Asp-Leu-Glu-Arg-Asp-His-Arg-Pro-His-Val-Ser-Met-Pro-Gln-Asn-Ala-Asn
Locustachykinin I Gly-Pro-Ser-Gly-Phe-Tyr-Gly-Val-Arg-NH2
Melanocyte Protein PMEL 17 (44-59) (human, bovine, mouse) Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp
Neuromedin (U25), human Phe-Arg-Val-Asp-Glu-Glu-Phe-Gln-Ser-Pro-Phe-Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2
Orexin A, bovine, human, mouse, rat Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2(Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
乳腺癌和卵巢癌易感基因RAD51C抗体图片按理化性质和生物学功能,可将其分为IgM、IgG、IgA、IgE、IgD五类。
IgM抗体是免疫应答中首先分泌的抗体。它们在与抗原结合后启动补体的级联反应。它们还把入侵者相互连接起来,聚成一堆便于巨噬细胞的吞噬;
IgG抗体激活补体,中和多种毒素。IgG持续的时间长,是 唯一能在母亲妊娠期穿过胎盘保护胎儿的抗体。他们还从乳腺分泌进入初乳,使新生儿得 到保护;
IgA抗体进入身体的黏 膜表面,包括呼吸、消化、生殖等管道的黏膜,中和感染因子。还可以通过母乳的初乳把这种抗体输送到新生儿的消化道黏膜中,是在母乳中含量最多,最为重要的一类抗体;
IgE抗体的尾部与嗜碱细胞、肥大细胞的细胞膜结合。当抗体与抗原结合后,嗜碱细胞与肥大细胞释放组织胺一类物质促进炎症的发展。这也是引发速发型过敏反应的抗体;
IgD抗体的作用还不太清楚。它们主要出现在成熟的B淋巴细胞表面上,可能与B细胞的分化有关。(IgD于1995年从人骨髓瘤蛋白中发现,分子量为175kD,主要由扁桃体、脾等处浆细胞产生,人血清中IgD浓度为3~40μg/ml,不到血清总Ig的1%,在个体发育中合成较晚。IgD铰链区很长,且对蛋白酶水解敏感,因此IgD半衰期很短,仅2.8天。血清中IgD确切的免疫功能尚不清楚。在B细胞分化到成熟B细胞阶段,除了表达SmIgD,抗原刺激后表现为免疫耐受。成熟B细胞活化后或者活化后或者变成记忆B细胞时,SmIgD逐渐消失。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验检测水平的肺癌预后评估方法,此研究成果发表在2012年柳叶刀杂志上。除肺癌外,在乳腺癌研究中,多采用靶向筛选HER2基因、易感基因筛查BRCA1/2基因、乳腺癌21基因图谱、化学预测TOP2A等检测技术,实现乳腺癌的靶向筛查、化疗预测、预后评估综合防治目标。目前,分子病理应用较为成熟的癌种还包括消化道癌症、肾癌等,其中肾癌靶向治疗药物均为间接影响HIF通路,以酪氨酸激酶抑制剂为主广泛应用于肾癌的一、二线治疗。卵巢癌靶向治疗的进步需要分子病理的推进卵巢癌常规治疗途径。卵巢癌在早期很难发现,很多病人发现时已是
与基因稳定性有关的基因 与基因 稳定性有关的基因主要是乳腺癌易感基因―1(BRCA―1),它位于17q21,是熟知的乳腺癌易感基因。用反义核酸技术抑制BRCAl的表达,可增加正常及恶性乳腺细胞的增殖,而野生型BRCAl的过度表达可抑制MCF―7等乳腺癌细胞在小鼠体内的成瘤能力。在近一半的遗传性乳腺肿瘤中发现BRCAl的遗传性突变。与其他抑癌基因不同的是,尽管在乳腺癌及卵巢癌中BRCAl基因发生LOH的频率很高,但其体细胞突变很少见。既然在散发性乳腺癌中
―patellasyndrome)和乳糖耐受不良症(1actoseintolerance)等。 定位克隆策略在单基因疾病上获得的巨大成功促使人们将这一研究策略应用于常见的复杂疾病。但迄今为止,对于糖尿病等大多数常见的多基因疾病,鲜有用定位克隆技术获得相关基因的成功报道。仅有的少数成功报道提示,严格选择研究样本有着重要意义,如采用发病年龄早的家系(接近孟德尔方式遗传),成功的例子有发现BRACl和BRAC2在乳腺癌和卵巢癌中的作用,以及hMSH2基因突变与遗传性非息肉性结肠
技术资料暂无技术资料 索取技术资料










